Cell therapy biotech Wugen secured $115 million in financing led by Fidelity Management to advance WU-CART-007, an allogeneic 'off-the-shelf' CAR-T treatment targeting relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoma. The therapy has shown high response rates in early trials, aiming for FDA approval submission in 2027. Wugen's approach offers a more accessible alternative to autologous CAR-T therapies by utilizing donor-derived cells, positioning the company at the forefront of innovative cell therapy development.